Nitrogen Or Sulfur Patents (Class 424/78.27)
-
Publication number: 20120282211Abstract: We provide methods and compositions for the treatment of dysregulation of blood vessel growth by regulation of neovascularization. Embodiments accomplish this by restricting the diffusion and transport of therapeutic agents through conjugating them to polymers or polymer constructs while retaining the binding affinities and functions of the therapeutic agents.Type: ApplicationFiled: November 24, 2010Publication date: November 8, 2012Applicant: CARNEGIE MELLON UNIVERSITYInventors: Newell R. Washburn, Liang Tso Sun
-
Publication number: 20120276041Abstract: A biological coating material that includes a polymerizable polyacrylate monomer; a volatile liquid; a polymer selected from a synthetic rubber, a natural rubber, and a thermoplastic elastomer. The biological liquid coating material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin of a user inhibits the application surface from adhering to another surface.Type: ApplicationFiled: April 30, 2012Publication date: November 1, 2012Applicant: ROCHAL INDUSTRIES, LLP.Inventors: Ann Beal Salamone, Joseph C. Salamone
-
Publication number: 20120269897Abstract: Described herein are nitric oxide (NO)-donating poly(tetrafluoroethylene) (PTFE) polymers and polymer surfaces and methods of making and using the same. The NO-donating PTFE polymers can be used to fabricate at least a portion of an implantable medical device, coat at least a portion of an implantable medical device or form at least a portion of an implantable medical device. The NO-donating PTFE polymers provide controlled release of NO once implanted at or within the target site.Type: ApplicationFiled: June 29, 2012Publication date: October 25, 2012Applicant: MEDTRONIC VASCULAR, INC.Inventors: Mingfei CHEN, Ayala HEZI-YAMIT
-
Patent number: 8283434Abstract: Methods for preparing a poly(ether carbonates) of the formula HO—[(CH2CH2—O)n—CO2]m—(CH2CH2—O)n—H are provided. The method comprises polymerizing an activated oligomer of the formula of H—O—(CH2CH2—O)n—CO2—Z, where Z is reactive leaving group.Type: GrantFiled: January 5, 2012Date of Patent: October 9, 2012Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Michael David Bentley, Xuan Zhao, Xiaoming Shen
-
Patent number: 8273828Abstract: Biocompatible polymers having polymer backbones with at least one secondary amine suitable for diazeniumdiolation are disclosed. Specifically, methods for providing secondary amines-containing polymers using epoxide-opening reactions are provided. More specifically, nitric oxide-releasing medical devices made using these polymers are disclosed.Type: GrantFiled: July 24, 2007Date of Patent: September 25, 2012Assignee: Medtronic Vascular, Inc.Inventors: Mingfei Chen, Peiwen Cheng, Kishore Udipi
-
Patent number: 8263063Abstract: Disclosed are conjugates exhibiting VLA-4 antagonistic properties. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. The conjugates of this invention are characterized as containing more than one VLA-4 inhibiting compound covalently attached to a bio-compatible polymer, such as polyethylene glycol. Conjugates of the invention are defined by formula I, wherein A, B, and q are described in the specification. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: September 8, 2010Date of Patent: September 11, 2012Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei W. Konradi, Michael A. Pleiss, Christopher M. Semko, Theodore Yednock, Jenifer L. Smith
-
Publication number: 20120189571Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.Type: ApplicationFiled: February 4, 2010Publication date: July 26, 2012Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL., INC.Inventors: Shiladitya Sengupta, Abhimanyu Paraskar, Shivani Soni, Sudipta Basu, Poulomi Sengupta
-
Patent number: 8216561Abstract: The present invention relates to a bio-stable hydrogel for use in the treatment and prevention of incontinence and vesicouretal reflux. The hydrogel is obtainable by combining acrylamide and methylene bis-acrylamide in amounts to provide about 0.5 to 25% by weight polyacrylamide, based on the total weight of the hydrogel.Type: GrantFiled: August 31, 2006Date of Patent: July 10, 2012Assignee: Contura A/SInventor: Jens Petersen
-
Patent number: 8217123Abstract: Disclosed are water soluble polymeric reagents comprising the structure POLY-[Y—S—W]x, where POLY is a water soluble polymer; Y is a hydrocarbon-based spacer group, x is 1 to 25, and S—W is a thiol, protected thiol, or thiol-reactive derivative. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are conjugates of such polymeric reagents with pharmaceutically relevant molecules, and methods of their formation and use.Type: GrantFiled: November 10, 2010Date of Patent: July 10, 2012Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Samuel P. McManus
-
Publication number: 20120148521Abstract: Methods and compositions for controlled release of amine, alcohol and thiol drugs, e.g., narcotic analgesics, and tricyclic amine antidepressants, are provided. The drug is releasably covalently bonded to a polymer or other activity-blocking moiety. Release is by an unmasking reaction resulting in the formation of a chemical group that undergoes a second reaction releasing the drug. For example, the narcotic analgesic fentanyl covalently attached to an inert polymer by way of its nitrogen through formation of a quaternary vinylammonium salt is released by hydrolysis of an acetal exposing an alcohol that undergoes an intramolecular nucleophilic substitution reaction involving displacement of the fentanyl nitrogen. Process rate is controlled by controlling the rate of the intramolecular substitution reaction through varying the number of atoms in the chain connecting the alcohol group and the vinylic carbon and/or by the addition of substituents on that chain, and/or by the acetal hydrolysis rate.Type: ApplicationFiled: December 21, 2011Publication date: June 14, 2012Inventor: Robert C. Corcoran
-
Publication number: 20120141409Abstract: The present invention provides an adjuvant-polymer construct comprising a polymer backbone which is covalently linked to 3 or more adjuvants, wherein the 3 or more adjuvants are each present in a pendant side chain, the adjuvants being connected to the polymer backbone either directly or via a spacer group.Type: ApplicationFiled: May 7, 2010Publication date: June 7, 2012Applicant: PSIOXUS THERAPEUTICS LIMITEDInventors: Leonard Charles William Seymour, Kerry Fisher
-
Publication number: 20120107264Abstract: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.Type: ApplicationFiled: October 13, 2011Publication date: May 3, 2012Applicant: Nitto Denko CorporationInventors: Padmanabh Chivukula, Jian Liu, Akinobu Soma, Keisaku Okada, Sang Van, Julia Zhu, Nianchun Ma, Chen-Chang Lee, Fu Chen, Lei Yu
-
Publication number: 20120093763Abstract: Disclosed herein is an RNA virus infection inhibitor that is capable of effectively inhibiting humans from being infected with RNA viruses to prevent the occurrence of symptoms or, even when symptoms occur, to relieve the symptoms and is less likely to cause unexpected discoloration or discoloration under normal service conditions. The RNA virus infection inhibitor comprises an RNA virus infection-inhibiting compound comprising a linear polymer having, in its side chain, at least one of substituents having structural formulas represented by general formulas (1) to (3).Type: ApplicationFiled: June 16, 2010Publication date: April 19, 2012Inventors: Takayuki Akamine, Akihiko Fujiwara, Taro Suzuki
-
Publication number: 20120065614Abstract: A new technique to stabilize transition metal phosphors in a wide variety of stimuli-sensitive polymers and gels is disclosed herein. Other than stabilization in stimuli sensitive/biocompatible matrix some of these transition metal based phosphors are also shown to act as phosphorescent crosslinkers that physically or chemically crosslink polymeric chains to form micro/nanoparticles. The microspheres/nanospheres of the present invention show decreased size and photoluminescence enhancement with particularly high sensitization at physiological pH and temperature. The so formed phosphorescent micro/nanospheres are useful for biological or environmental applications including biological labeling, imaging, and optical sensing. The techniques in the present invention enable usage of imaging agents and sensors at very low concentrations and also minimize or eliminate the usage of toxic chemical crosslinkers typically used to synthesize polymeric micro/nanoparticles.Type: ApplicationFiled: September 9, 2011Publication date: March 15, 2012Applicant: UNIVERSITY OF NORTH TEXASInventors: Mohammad A. Omary, Zhibing Hu, Sreekar Marpu
-
Publication number: 20120058077Abstract: Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film may be formed in situ by coating the surface with a solution or emulsion comprising a polyvinyl alcohol and a quaternary ammonium compound and then causing or allowing it to dry or substantially dry.Type: ApplicationFiled: November 10, 2011Publication date: March 8, 2012Applicant: Novapharm Research (Australia) PTY LTDInventor: Steven Kritzler
-
Publication number: 20120052006Abstract: The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.Type: ApplicationFiled: February 17, 2010Publication date: March 1, 2012Applicant: COLORADO SCHOOL OF MINESInventors: Stephen G. Boyes, Misty D. Rowe
-
Patent number: 8119756Abstract: Methods for delivering a biologically active agent into the body of a mammal are provided, the method comprising administering a carbamate-containing conjugate to the mammal.Type: GrantFiled: February 14, 2011Date of Patent: February 21, 2012Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Michael D. Bentley, Xuan Zhao, Xiaoming Shen
-
Patent number: 8105570Abstract: This invention provides a method and compositions for the controlled release of drugs that have been attached by means of a covalent bond to a polymer or other moiety that blocks activity of the drug until it has been released. A two-stage process is provided in which an unmasking reaction results in the formation of a chemical group that can then undergo a second reaction to release the drug. In a preferred embodiment, the narcotic analgesic fentanyl covalently attached to an inert polymer by way of its nitrogen through the formation of a quaternary vinylammonium salt, and then released by a sequence involving hydrolysis of an acetal that exposes an alcohol that may then undergo an intramolecular nucleophilic substitution reaction involving displacement of the nitrogen of oxycodone.Type: GrantFiled: June 1, 2004Date of Patent: January 31, 2012Assignee: The University of WyomingInventor: Robert C. Corcoran
-
Publication number: 20120003176Abstract: A hydrogel composition is formed from a natural polymer derivative having a plurality of cross-linkable units depending therefrom, and a synthetic polymer derivative having a plurality of cross-linkable units depending therefrom, said natural and synthetic polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of natural and synthetic polymers provides for biodegradability of the hydrogel, along with mechanical properties such as strength and elasticity.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicant: Zimmer Orthobiologics, Inc.Inventors: Xiao Huang, Jian Q. Yao, Jizong Gao, Victor Zaporojan, Joe Zhe Guo
-
Publication number: 20110293675Abstract: An implantable device including conjugate formed of an acrylamide-based copolymer and a bioactive agent is provided.Type: ApplicationFiled: August 9, 2011Publication date: December 1, 2011Applicant: Advanced Cardiovascular Systems, Inc.Inventors: Syed F.A. Hossainy, Thierry Glauser, Mikael O. Trollsas
-
Patent number: 8058344Abstract: The present invention relates to new anionic glycodendrimers having new biological activity, processes for preparing them and their use in medicine including veterinary medicine.Type: GrantFiled: March 18, 2003Date of Patent: November 15, 2011Assignee: Imperial Innovations LtdInventors: Sunil Shaunak, Elisabetta Gianasi, Ruth Duncan
-
Systems and methods that kill infectious agents (bacteria) without the use of a systemic anti-biotic
Publication number: 20110200655Abstract: A medical product is provided that is selected from at least one of, nasal cannulas, oxygen masks, wound dressings, bandages, band aids, catheters, endotrachial tubes, condoms, surgical and other gloves, sheaths for endoscopy probes, and medical products that physically touch the body. A coating is included with at least one of, a non-antibiotic, antimicrobial and/or antiviral substance that prevents further local, non-systemic, colonization of infections.Type: ApplicationFiled: February 16, 2011Publication date: August 18, 2011Inventors: Michael Darryl Black, Anita Margarette Chambers -
Patent number: 7985414Abstract: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.Type: GrantFiled: January 19, 2006Date of Patent: July 26, 2011Assignee: Warsaw Orthopedic, Inc.Inventors: David Knaack, John Winterbottom, David Kaes, Todd Boyce, Larry Shimp
-
Publication number: 20110171167Abstract: The present disclosure describes a method and a kit for bulking, augmenting or occluding a tissue comprising administering a sufficient amount of a composition containing a biocompatible, non-bioabsorbable isocyanate-based material onto or into tissue.Type: ApplicationFiled: June 30, 2005Publication date: July 14, 2011Applicant: TYCO HEALTHCARE GROUP LPInventor: Scott Herring
-
Patent number: 7976834Abstract: The invention provides a multi-arm block copolymer for use in delivering a variety of bioactive agents. The copolymer of the invention contains a central core from which extend multiple (3 or more) copolymer arms. Each copolymer arm possesses an inner polypeptide segment and an outer hydrophilic polymer segment. Thus, the overall structure of the copolymer comprises an inner core region that includes the central core and the inner polypeptide segment, while the outer core region is hydrophilic in nature. The multi-arm copolymer of the invention is particularly useful for delivery of biologically active agents that can be entrapped within the inner core region.Type: GrantFiled: November 14, 2007Date of Patent: July 12, 2011Assignee: Nektar TherapeuticsInventors: Xuan S. Zhao, Zhongxu Ren, Kazunori Emoto
-
Publication number: 20110165114Abstract: There is provided a non-water soluble drug delivery composition comprising a conjugate and a polymer matrix wherein exposure of the composition to electromagnetic radiation at a suitable pre-determined wavelength and intensity induces release of the active ingredient from the composition. The conjugate is attached to the polymer matrix through non-covalent interactions. There is also provided a drug delivery apparatus formed from the drug delivery composition.Type: ApplicationFiled: May 28, 2009Publication date: July 7, 2011Inventors: Colin Peter McCoy, Sean Patrick Gorman, David Simon Jones
-
Patent number: 7968085Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: GrantFiled: October 7, 2004Date of Patent: June 28, 2011Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Publication number: 20110142764Abstract: Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed.Type: ApplicationFiled: May 21, 2009Publication date: June 16, 2011Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Ronit Satchi-Fainaro, Keren Miller, Doron Shabat, Rotem Erez
-
Publication number: 20110135831Abstract: Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film may be formed in situ by coating the surface with a solution or emulsion comprising a polyvinyl alcohol and a quaternary ammonium compound and then causing or allowing it to dry or substantially dry.Type: ApplicationFiled: February 14, 2011Publication date: June 9, 2011Applicant: Novapharm Research (Australia) Pty Ltd.Inventor: Steven Kritzler
-
Patent number: 7947261Abstract: Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.Type: GrantFiled: March 23, 2006Date of Patent: May 24, 2011Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
-
Patent number: 7947263Abstract: Biocompatible synthetic macromer compositions are provided including a first polymer having multiple functional groups and a second functionalized polyurethane prepolymer, which can be employed as an adhesive or sealant for medical/surgical uses.Type: GrantFiled: December 6, 2006Date of Patent: May 24, 2011Assignee: Tyco Healthcare Group LPInventors: Ahmad R. Hadba, Nadya Belcheva, John Kennedy, Mark Roby
-
Patent number: 7947262Abstract: Mast cell (MC) and peripheral blood basophil (PBB)-associated diseases are treated or prevented, or their symptoms are alleviated by the administration of water soluble fullerenes (buckeyballs) to the individual under conditions sufficient to inhibit MC and PBB responses. MC and PBB responses are associated with, for example, various allergies including Type 1 hypersensitivity initiated by IgE-antigen, arthritis, multiple sclerosis, urticaria, atopic dermatitis, heart disease, etc. The treatment regimen can be enhanced using Chimeric fullerenes that specifically home to and inhibit MC and PBB cells. These molecules, for example, comprise fullerenes to which are attached IgE Fc or stem cell factor (SCF) peptides that bind to receptors specifically on MC and PBB cells. Additional molecules which may be used in the processes include IgE Fc or SCF peptides with several fullerenes covalently attached.Type: GrantFiled: September 26, 2006Date of Patent: May 24, 2011Assignee: Virginia Commonwealth UniversityInventor: Chris Kepley
-
Publication number: 20110117164Abstract: A method for increasing, prolonging, and/or controlling the release rates of nitric oxide (NO) from polymeric materials containing NO adducts. Such NO-containing polymeric materials may find use in devices such as blood contacting devices, and biocompatible devices utilizing the same. The method and device utilizes anionic site additives, acidic site additives and/or acidic producing site additives in a polymer that contains NO-adducts to generate higher fluxes of NO to exceed NO threshold levels desirable to substantially prevent and/or minimize reactions such as platelet activation or adhesion.Type: ApplicationFiled: August 5, 2010Publication date: May 19, 2011Inventors: Mark E. Meyerhoff, Melissa M. Reynolds, Zhengrong Zhou
-
Publication number: 20110110882Abstract: Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).Type: ApplicationFiled: June 18, 2009Publication date: May 12, 2011Inventors: Orahn Preiss-Bloom, Ishay Attar, Natalie Iram, Chagai Komlos, Meir Haber
-
Patent number: 7939055Abstract: A polymer comprises a monomer having a N-halo sulfonamide pendant group and having the formula: wherein A is a trivalent linkage; wherein Q is a divalent linkage and y is 0 or 1; wherein R1, R2, R3, and R4 are as described within; wherein X is halogen; and wherein M is an alkali or alkaline earth metal. In specific embodiments, R1, R2, R3, and R4 are hydrogen; X is chlorine; and M is sodium or potassium.Type: GrantFiled: March 20, 2007Date of Patent: May 10, 2011Inventors: Charles A. Schneider, David J. Schneider
-
Publication number: 20110097376Abstract: A composition suitable for use as replacement material for all or part of a disc nucleus during percutaneous injection, the composition comprising: an injectable, curable, cross-linkable, non-immunogenic non-toxic protein hydrogel that (i) the protein component of the protein hydrogel contains at least one crosslinkable amino acid (ii) has a static compressive modulus of at least about 10 kPa, and (iii) has a dynamic compressive modulus of at least about 10 kPa; an iodinated contrast solution comprising an amount of an iodine compound sufficient to increase radiopacity to a discernable level, wherein the solution causes a decrease in the static and/or dynamic compressive modulus; and an amount of a crosslinker sufficient to restore at least about 100% of the decrease in static and/or dynamic compressive modulus caused by addition of the iodinated contrast solution.Type: ApplicationFiled: October 27, 2009Publication date: April 28, 2011Applicant: SPINE WAVE, INC.Inventors: Ulrich Berlemann, Thomas G. Wilson, Peter Wronski, Thomas Douville
-
Patent number: 7927619Abstract: The present invention relates to a hydrated, biocompatible tissue-augmentation compound and methodology for its implantation into mammalian tissue. The tissue-augmentation compound is comprised of: living tissue, optionally body derived fluids, and at least one NCO-terminated hydrophilic urethane prepolymer derived from an organic polyisocyanate, and oxyethylene-containing diols or polyols in which essentially all of hydroxyl groups are capped with polyisocyanate.Type: GrantFiled: April 26, 2006Date of Patent: April 19, 2011Assignee: Promethean Surgical Devices LLCInventor: Michael T. Milbocker
-
Publication number: 20110076246Abstract: Sulfur-containing ligands and methods of their utilization for binding metals and/or main group elements and removing them from fluids, solids, gases and/or tissues are disclosed.Type: ApplicationFiled: September 28, 2010Publication date: March 31, 2011Inventors: Boyd E. Haley, David A. Atwood
-
Patent number: 7914776Abstract: Solid dispersions of stable, amorphous opioid antagonists, particularly [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid, with improved water solubility and bioavailability are disclosed. Also disclosed are methods of preventing or treating a side effect associated with an opioid. In addition, methods of treating or preventing pain, ileus, and opioid bowel dysfunction are disclosed.Type: GrantFiled: October 5, 2006Date of Patent: March 29, 2011Assignee: Adolor CorporationInventor: Virendra Kumar
-
Patent number: 7910685Abstract: Conjugates between a protein and a water soluble polymer comprising multiple degradable carbonate linkages are provided.Type: GrantFiled: June 29, 2010Date of Patent: March 22, 2011Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Michael D. Bentley, Xuan Zhao, Xiaoming Shen
-
Patent number: 7892834Abstract: A gene complex-forming material which comprises a water-soluble polymer having a peptide containing an amino acid sequence serving as the substrate of an intracellular signal-responsive enzyme and basic amino acids imparting cationic nature; a gene complex composed of this gene complex-forming material with a gene; and a gene transfer method and a gene transfer agent with the use of the same. Namely, a novel material and a method wherein the cationic moiety of the peptide and the gene form a rigid ion complex to give a stable gene complex, and, upon a cellular signal response, the positive charge of the cationic moiety of the peptide is neutralized or disappears and the gene complex is broken in the cell to thereby release the gene, thus activating the gene transferred into specific cells. The neutralization or disappearance of the positive charge can be achieved by, for example, phosphorylation with protein kinase A or cleavage by caspase.Type: GrantFiled: October 16, 2001Date of Patent: February 22, 2011Assignee: Japan Science and Technology AgencyInventor: Yoshiki Katayama
-
Patent number: 7879317Abstract: Polymeric compositions capable of forming stable micelles in an aqueous solution, comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block, and a polylactic acid derivative wherein one end of the polylactic acid is covalently bound to at least one carboxyl group. The carboxyl group of the polylactic acid derivative may be fixed with a di- or tri-valent metal ion, obtained by adding the di- or tri-valent metal ion to the polymeric composition.Type: GrantFiled: October 17, 2002Date of Patent: February 1, 2011Assignee: Samyang CorporationInventors: Min-Hyo Seo, Sa-Won Lee, Hee-Jo Kim, Jeong-Kyung Kim, Myung-Han Huyn, Jeong-il Yu, Bong-Oh Kim
-
Publication number: 20110014292Abstract: The present invention relates generally to a method of prophylactically or therapeutically treating antigen-induced airway tissue inflammation and agents for use therein. More particularly, the present invention provides a method of prophylactically or therapeutically treating allergic airway inflammation and agents for use therein via the administration of the method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by antigen-induced airway tissue inflammation.Type: ApplicationFiled: October 15, 2008Publication date: January 20, 2011Applicant: COOPERATIVE RESEARCH CENTRE FOR ASTHMAInventors: Robyn Elizabeth O'Hehir, Magda Plebanski, Jennifer Rolland, Charles Linton Hardy
-
Patent number: 7863408Abstract: A body fluid compatible and biocompatible resin for use in a medical treatment involving a contact of said resin with at least one member selected from the group consisting of a body fluid and a biological tissue, which comprises at least one substituted oxyalkylene polymer having a weight average molecular weight of from 1,000 to 1,000,000 and represented by the following formula (1): wherein each of R1, R2 and R3 independently represents a hydrogen atom or a —CH2R4 group, and each R4 independently represents a hydroxyl group or a —OR5 group (wherein R5 represents a group selected from the group consisting of a C1-C10 aliphatic hydrocarbyl group, a C6-C10 aryl group, a —R6COOH group and a derivative thereof, and a —CH2—O—CH2—CH(OH)—CH2—OR7 group, wherein R6 represents a C1-C10 aliphatic hydrocarbylene group and R7 represents a C1-C10 aliphatic hydrocarbyl group or a C6-C10 aryl group), provided that all of R1, R2, and R3 are not simultaneously hydrogen atoms; and 10?x?10,000 and 0?y?10,000.Type: GrantFiled: January 4, 2005Date of Patent: January 4, 2011Assignee: Asahi Kasei Kabushiki KaishaInventor: Shuichi Sugawara
-
Publication number: 20100330143Abstract: Described herein are composites produced by reacting a first thiolated macromolecule with at least one compound having at least one thiol-reactive electrophilic functional group. The methods described herein permit the cross-linking of a variety of different thiolated macromolecules with one another. The composites described herein have a variety of biomedical and pharmaceutical applications, which are also described herein.Type: ApplicationFiled: April 21, 2010Publication date: December 30, 2010Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Glenn D. Prestwich, Aleksander Skardal, Jianxing Zhang
-
Patent number: 7858078Abstract: Bioabsorbable macromer compositions are provided including a diisocyanate-functional bioabsorbable polymer. In some embodiments, the diisocyanate-functional bioabsorbable polymer can be combined with a functionalized polyol. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses.Type: GrantFiled: December 6, 2006Date of Patent: December 28, 2010Assignee: Tyco Healthcare Group LPInventors: Ahmad R. Hadba, Nadya Belcheva
-
Patent number: 7858079Abstract: Compositions provided by mixing a biotin-containing component and an avidin-containing component are useful as an adhesive or sealant for medical/surgical uses.Type: GrantFiled: February 28, 2007Date of Patent: December 28, 2010Assignee: Tyco Healthcare Group LPInventors: Ahmad R. Hadba, Joshua B. Stopek
-
Patent number: 7851565Abstract: Disclosed are water soluble polymeric reagents comprising the structure POLY-[Y—S—W]x, where POLY is a water soluble polymer; Y is a hydrocarbon-based spacer group, x is 1 to 25, and S—W is a thiol, protected thiol, or thiol-reactive derivative. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are conjugates of such polymeric reagents with pharmaceutically relevant molecules, and methods of their formation and use.Type: GrantFiled: December 21, 2005Date of Patent: December 14, 2010Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Samuel McManus
-
Patent number: 7803899Abstract: Various methods are described for preparing dry water-soluble polymers with reduced organic impurity content by combining water-soluble polymer in water with at least one dry polar solvent to form a mixture that separates into a first layer comprising a majority of the solvent and water and a second layer comprising a majority of the polymer, then separating the layers and drying the second layer to obtain a solid comprising the water-soluble polymer. Further, or solid polymer products having reduced organic impurity levels and/or moisture content are also described.Type: GrantFiled: September 27, 2006Date of Patent: September 28, 2010Assignee: Buckman Laboratories International, Inc.Inventors: Mark L. Zollinger, James Andrew Ward
-
Patent number: 7794700Abstract: Disclosed are conjugates exhibiting VLA-4 antagonistic properties. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. The conjugates of this invention are characterized as containing more than one VLA-4 inhibiting compound covalently attached to a bio-compatible polymer, such as polyethylene glycol. Conjugates of the invention are defined by formula I, wherein A, B, and q are described in the specification. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: July 8, 2005Date of Patent: September 14, 2010Assignee: Elan Pharmaceuticals Inc.Inventors: Andrei Konradi, Michael A. Pleiss, Christopher M. Semko, Theodore Yednock, Jenifer L. Smith